0
0
New Delhi, India – In a significant stride against the growing epidemic of obesity and type 2 diabetes, Eli Lilly and Co.has officially launched Mounjaro in India, marking the country’s first approved weight-loss drug. The American pharmaceutical giant’s tripeptide medication, already making waves globally, has received marketing approval from India’s Central Drugs Standard Control Organisation (CDSCO), placing Eli Lilly at the forefront of the burgeoning Indian market.
With India ranking third globally in obesity prevalence and housing approximately 100 million individuals grappling with both obesity and diabetes, the arrival of Mounjaro is a timely intervention. This launch positions Eli Lilly ahead of its competitors, particularly Novo Nordisk, which has yet to confirm the launch date of its own obesity drug, Wegovy, in India.
Affordable Pricing Strategy
Eli Lilly has adopted a notably competitive pricing strategy for the Indian market. Mounjaro will be available in single-dose vials, with the 2.5 mg dose priced at Rs 3,500 ($40.5) and the 5 mg dose at Rs 4,375. This pricing is significantly lower than in the United States, where a 2.5 mg vial costs approximately $568, making the Indian price nearly 14 times more affordable.
“This India-specific pricing reflects Lilly’s commitment to expanding access to innovative treatments in the country,” stated a company spokesperson.
Addressing Unregulated Market
The launch of Mounjaro aims to address the growing trend of individuals in India resorting to purchasing obesity drugs from unregulated sources. By providing a regulated and accessible option, Eli Lilly seeks to ensure patient safety and effective treatment.
Winselow Tucker, President of Lilly India, emphasized the urgency of the situation, stating, “The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India. Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases.”
The introduction of Mounjaro marks a pivotal moment in India’s healthcare landscape, offering a new avenue for managing obesity and diabetes. As the demand for effective weight-loss solutions continues to rise, Eli Lilly’s strategic pricing and early market entry are poised to make a substantial impact.
Disclaimer: This news article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional before starting any weight-loss or diabetes treatment. The information provided is based on available public information and may be subject to change. Individual results may vary.(https://www.freepressjournal.in/lifestyle/indias-first-weight-loss-drug-arrives-eli-lilly-launches-mounjaro-know-how-much-it-will-cost-you)
